Monte Rosa Therapeutics Inc (GLUE) 옵션

GLUE, under $7

Hmm

$GLUE investors have been in what Cramer calls "the house of pain" for months. Many purchased this at $40,$50,$60,$70 per share. The company will be added to the long list of biotech failures once the inevitable FDA trial failure is confirmed.

$GLUE will soon be added to this list

https://www.fiercebiotech.com/special-reports/2023s-top-10-clinical-trial-flops

$GLUE trapped alot of "investors" earlier this week at 10+ all the way to 12.50/Share. It is cratering just as precipitously. Watch for less than 8....7.....6... in days to come.

$GLUE - No products. no revenues, massive losses, running out of cash. Millions of shares avaiable to short. Looking for $5/share

GLUE under $7

GLUE under $6

GLUE under $5

GLUE under $5